@article{article_1639156, title={Prognostic significance of prognostic nutritional index in high-grade serous ovarian cancer: a comparative analysis with other prognostic factors}, journal={Cukurova Medical Journal}, volume={50}, pages={519–529}, year={2025}, DOI={10.17826/cumj.1639156}, author={Aladağ, Zeynep and Küçükgöz Güleç, Ümran and Paydaş, Semra and Güleç, Ersel and Khatib, Ganim and Vardar, Mehmet Ali}, keywords={Cancer antigen 125 (CA-125), high-grade serous ovarian cancer (HGSOC), prognostic nutrition index (PNI)}, abstract={Purpose: High-grade serous ovarian cancer (HGSOC) has high recurrence and mortality rates despite treatment advances. The prognostic nutritional index (PNI) shows promise in other cancers, but its role in HGSOC is unclear. This study aimed to evaluate PNI’s prognostic value in HGSOC and establish an optimal cutoff for mortality prediction. Materials and Methods: This retrospective cohort evaluated 332 patients with HGSOC from 2010-2020. The age range, body mass index (BMI), menopausal status, parity status, presence of comorbidities, American Society of Anesthesiologists (ASA) scores, the presence of ascites, cancer antigen 125 (CA-125), neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, disease stage, recurrence status, platinum resistance, attainment of optimal cytoreduction, and PNI were evaluated. PNI relationship with other factors affecting prognosis was evaluated. Results: The Mean PNI was 41.8±8.7, with a cutoff of ≤44.6 (96.84% sensitivity, 81.69% specificity) for mortality prediction. PNI was a stronger predictor (AUC=0.932) than CA-125 (AUC=0.588). Low PNI (≤44.6) was significantly linked with advanced disease, platinum resistance, preoperative ascites ≥ 1 L, more recurrences, lower 5-year survival, and higher mortality. Multivariate analysis showed low PNI as an independent mortality predictor (OR: 136.82, 95% CI: 54.6-342.4), along with preoperative ascites > 1 L and disease recurrence. Conclusion: A low preoperative PNI strongly predicts higher mortality in HGSOC patients than in CA-125 patients. This accessible and cost-effective biomarker may aid in assessing risks, guiding increased monitoring, and customizing treatments. Further studies are necessary to confirm these results in various populations.}, number={2}, publisher={Cukurova University}